Extrawell Pharmaceutical Holdings Limited (HK:0858)
:0858
Top Page
Extrawell Pharmaceutical Holdings Limited
(0858)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.08
▼(-11.11% Downside)
Action:ReiteratedDate:11/19/25
Extrawell Pharmaceutical's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and cash flow issues. The technical analysis suggests bearish momentum, while the valuation indicates potential undervaluation. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Low Leverage
A low debt-to-equity ratio (0.11) reduces financial risk and interest burden, giving management flexibility to prioritize operations, working capital, or targeted investments. Over a 2–6 month horizon this balance sheet buffer supports stability during revenue recovery and preserves borrowing capacity for strategic actions.
Negative Factors
Declining Revenues
Material revenue declines (annual decrease ~7.2% and recent growth trend -11.9%) erode scale and pricing power, reducing gross margin and fixed-cost absorption. Sustained top-line weakness over several quarters will limit cash generation, reduce investment capacity, and make operational turnarounds more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A low debt-to-equity ratio (0.11) reduces financial risk and interest burden, giving management flexibility to prioritize operations, working capital, or targeted investments. Over a 2–6 month horizon this balance sheet buffer supports stability during revenue recovery and preserves borrowing capacity for strategic actions.
Read all positive factors
Extrawell Pharmaceutical Holdings Limited (0858) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$211.65M
Dividend YieldN/A
Average Volume (3M)2.87M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth-11.89%
EPS Growth-290.48%
CountryHK
Employees162
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.19
Shares Outstanding2,550,000,000
10 Day Avg. Volume3,479,000
30 Day Avg. Volume2,870,000
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.08
Price to Sales (P/S)1.94
P/FCF Ratio-14.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and G...
How the Company Makes Money
null...
Extrawell Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
30
Negative
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.43M | 59.10M | 72.58M | 73.92M | 78.80M |
| Gross Profit | 21.87M | 28.78M | 31.14M | 37.56M | 42.57M |
| EBITDA | 255.11M | -129.52M | 155.20M | 157.84M | -97.48M |
| Net Income | 222.64M | -162.95M | 129.26M | 130.59M | -121.10M |
Balance Sheet | |||||
| Total Assets | 1.53B | 1.29B | 1.44B | 1.32B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 994.86M | 95.01M | 123.96M | 135.52M | 150.18M |
| Total Debt | 140.94M | 120.41M | 615.58M | 597.67M | 586.23M |
| Total Liabilities | 191.55M | 174.58M | 671.28M | 659.53M | 642.36M |
| Stockholders Equity | 1.33B | 1.11B | 769.36M | 653.29M | 518.15M |
Cash Flow | |||||
| Free Cash Flow | -7.44M | -4.89M | -3.40M | -11.23M | -953.00K |
| Operating Cash Flow | -4.37M | -3.69M | 3.21M | -1.60M | -232.00K |
| Investing Cash Flow | -9.38M | 2.04M | -12.50M | -9.63M | -681.00K |
| Financing Cash Flow | -1.58M | -6.50M | -2.29M | -1.80M | -1.69M |
Extrawell Pharmaceutical Holdings Limited Technical Analysis
Neutral
0.09
Price Trends
0.08
Negative
0.08
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
49.35
Neutral
71.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0858, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 71.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0858.
Extrawell Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$211.65M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$47.44M | 7.84 | -3.06% | ― | -40.37% | -112.64% | |
49 Neutral | HK$933.73M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$177.84M | -40.12 | -8.95% | ― | 2.54% | 33.33% | |
44 Neutral | HK$167.36M | -0.14 | -43.61% | ― | 6.55% | -475.22% | |
42 Neutral | HK$168.51M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
0.04
76.60%
HK:0911
Qianhai Health Holdings Ltd.
0.28
0.06
27.27%
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
25.00%
HK:1498
PuraPharm Corp. Ltd.
0.32
-0.20
-38.24%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.27
1.03
429.17%
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.04
15.00%
Extrawell Pharmaceutical Holdings Limited Corporate Events
Extrawell Pharma Weighs HK$715 Million Sale of Starcoin Convertible Bonds
Mar 27, 2026
Extrawell Pharmaceutical Holdings has entered into a non-legally binding memorandum of understanding with a potential purchaser regarding the possible sale of all its convertible bonds in Starcoin, with a total principal amount of HK$715 million, ...
Extrawell Pharmaceutical Lifts Stake in Key Subsidiary via Share Buy-Back
Mar 17, 2026
Extrawell Pharmaceutical Holdings Limited has completed a share buy-back and cancellation at its 80.46% indirectly owned subsidiary Changchun Extrawell, following fulfillment of all conditions on 16 March 2026. After the transaction, Changchun Ext...
Extrawell Pharmaceutical Extends Bond Amendment Long Stop Date and Delays Shareholder Circular
Feb 27, 2026
Extrawell Pharmaceutical has agreed with bondholder Starcoin to extend the long stop date for completing the fourth set of amendments to its bond terms from 31 March 2026 to 30 June 2026. The change allows more time to satisfy precedent conditions...
Extrawell Pharmaceutical Revamps Board with New Independent Director Appointment
Jan 20, 2026
Extrawell Pharmaceutical Holdings has announced board and committee changes effective 20 January 2026, with long-serving independent non-executive director (INED) Fang Lin Hu resigning from the board and from his roles as chairman of the audit and...
Extrawell Pharmaceutical Sets Out Board and Committee Line-Up
Jan 20, 2026
Extrawell Pharmaceutical Holdings Limited has announced the current composition of its board of directors, led by Chairman Dr. Xie Yi and Chief Executive Officer Dr. Guo Yi, alongside a team of executive and independent non-executive directors. Th...
Extrawell Pharmaceutical Updates Building Name of Hong Kong Head Office
Dec 31, 2025
Extrawell Pharmaceutical Holdings Limited has announced that, effective 1 January 2026, the building name of its Hong Kong head office and principal place of business will change from Devon House to FWD Tower, with the full updated address now sta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.